These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 2108739)
21. The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison. Hay CR; Ludlam CA; Lowe GD; Mayne EE; Lee RJ; Prescott RJ; Lee CA Br J Haematol; 1998 Jun; 101(4):632-7. PubMed ID: 9674733 [TBL] [Abstract][Full Text] [Related]
22. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients]. Briët E; Mauser-Bunschoten EP Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158 [TBL] [Abstract][Full Text] [Related]
23. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates. Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099 [TBL] [Abstract][Full Text] [Related]
24. [Gene therapy for hemophilia: feasible in principle but not yet clinically applicable]. van der Eb MM; Schagen FH; van Ormondt H; Hoeben RC Ned Tijdschr Geneeskd; 1998 Apr; 142(15):840-4. PubMed ID: 9623157 [TBL] [Abstract][Full Text] [Related]
25. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D; Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442 [TBL] [Abstract][Full Text] [Related]
26. Transfusion-transmitted disease. Lee CA Baillieres Clin Haematol; 1996 Jun; 9(2):369-94. PubMed ID: 8800511 [TBL] [Abstract][Full Text] [Related]
27. Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate. Evatt BL; Austin H; Leon G; Ruiz-Sáez A; De Bosch N Haemophilia; 1999 Sep; 5(5):295-300. PubMed ID: 10583509 [TBL] [Abstract][Full Text] [Related]
28. Infection of hemophiliacs with HIV. Aronson DL J Clin Apher; 1993; 8(2):117-9. PubMed ID: 8226704 [TBL] [Abstract][Full Text] [Related]
29. Changing paradigm of prophylaxis with longer acting factor concentrates. Carcao M Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284 [TBL] [Abstract][Full Text] [Related]
30. Exposure to acellular blood products and risk of HIV infection in hemophiliacs from Belo Horizonte, Brazil. Proietti FA; Proietti AB; Costa MF; Antunes CM; Guimarães MD; Paulino UH; Souza CJ; Melo L; Muñoz A Rev Inst Med Trop Sao Paulo; 1992; 34(3):227-32. PubMed ID: 1342075 [TBL] [Abstract][Full Text] [Related]
31. Viral safety of plasma-derived factor VIII and IX concentrates. Ludlam CA Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532 [TBL] [Abstract][Full Text] [Related]
32. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE Cochrane Database Syst Rev; 2015 Dec; (12):CD011385. PubMed ID: 26704192 [TBL] [Abstract][Full Text] [Related]
33. Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate. Schimpf K; Brackmann HH; Kreuz W; Kraus B; Haschke F; Schramm W; Moesseler J; Auerswald G; Sutor AH; Koehler K N Engl J Med; 1989 Oct; 321(17):1148-52. PubMed ID: 2507917 [TBL] [Abstract][Full Text] [Related]
34. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. Smith KJ; Lusher JM; Cohen AR; Salzman P Semin Hematol; 1990 Apr; 27(2 Suppl 2):25-9. PubMed ID: 2128855 [TBL] [Abstract][Full Text] [Related]
35. Treatment type and amount influenced human immunodeficiency virus seroprevalence of patients with congenital bleeding disorders. Gjerset GF; Clements MJ; Counts RB; Halvorsen AS; Thompson AR Blood; 1991 Sep; 78(6):1623-7. PubMed ID: 1884029 [TBL] [Abstract][Full Text] [Related]
36. Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Transfusion Safety Study Group. Dietrich SL; Mosley JW; Lusher JM; Hilgartner MW; Operskalski EA; Habel L; Aledort LM; Gjerset GF; Koerper MA; Lewis BH Vox Sang; 1990; 59(3):129-35. PubMed ID: 2124751 [TBL] [Abstract][Full Text] [Related]
37. [Post-transfusion hepatitis and its sequelae in the treatment of hemophilia]. Schimpf K Behring Inst Mitt; 1983 Aug; (73):111-7. PubMed ID: 6433878 [TBL] [Abstract][Full Text] [Related]
38. Outbreaks of hepatitis A and emergence of new AIDS-associated agents: the need to add terminal 100 degrees C dry-heat sterilization to factor VIII and factor IX concentrates. Guillaume TA Vox Sang; 1993; 65(2):158. PubMed ID: 8212671 [No Abstract] [Full Text] [Related]
39. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)]. Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353 [TBL] [Abstract][Full Text] [Related]
40. Financing the rising cost of haemophilia care at a large comprehensive care centre. Miners AH; Sabin CA; Stevens AJ; Tolley KH; Lee CA J R Coll Physicians Lond; 1997; 31(6):640-4. PubMed ID: 9409497 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]